HopeStage
Back to all studies
TerminatedNCT00570063

Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo

This study evaluates the safety and effectiveness of PF-02545920 for people with schizophrenia.

Placebo comparisonAges 18–99United States
The study in practice

Understand this study

What is this study about?

This study evaluates the safety and effectiveness of PF-02545920 for people with schizophrenia.

Who could participate?

Listed age limits: 18 years to 99 years.

Listed locations
Glendale and 9 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: November 2007
Recruitment status
Terminated
Enrollment listed in the registry
35
Sponsor
Pfizer
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 99 Years
Official registry ID
NCT00570063
Official title
Show the full official title

A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia

Recruitment & locations

Terminated

Glendale · Lemon Grove · Paramount

4 more locations
  • San Diego
  • New Haven
  • Willingboro
  • Oklahoma City

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

This study evaluates the safety and effectiveness of PF-02545920 for people with schizophrenia.

Who is behind this study?

The study sponsor is Pfizer.

Does this study involve medication?

Yes. The study involves medication, including PF-02545920 and Placebo.

Who can participate?

Listed age limits: 18 years to 99 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies